NicholaosCBellosMDFIDSA FACP(He/Him)

PubMed

• 62 citations
  Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppre...
  François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel E. Gallant, Eric S. Daar, Keith Henry, Jorge Santana-Bagur, David Stein, Nicholaos C. Bellos, Anthony ...> ;Journal of Acquired Immune Deficiency Syndromes. 2017 Jun 1
• 24 citations
  ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine
  Kathleen Squires, Benjamin Young, Edwin DeJesus, Nicholaos C. Bellos, Daniel Murphy, Douglas J. Ward, Henry H. Zhao, Lisa L. Ross, Mark S. Shaefer> ;HIV Clinical Trials. 2012 Sep 1
• 5 citations
  Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
  Daniel J. Skiest, Calvin J. Cohen, Karam Mounzer, Zach Haigney, David Barker, Michael S. Gottlieb, Paul Bellman, Edwin DeJesus, Homayoon Khanlou, Peter Ruane, Chiu-Bin...> ;HIV Clinical Trials. 2011 May 1
• 52 citations
  Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine pl...
  Kathleen Squires, Benjamin Young, Edwin DeJesus, Nicholaos C. Bellos, Daniel Murphy, Henry H. Zhao, Lisa G. Patel, Lisa L. Ross, Paul Wannamaker, Mark S. Shaefer> ;AIDS. 2010 Aug 24
• 174 citations
  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
  Kimberly Y. Smith, Parul Patel, Derek M. Fine, Nicholaos C. Bellos, Louis Sloan, Philip Lackey, Princy Kumar, Denise H Sutherland-Phillips, Cindy Vavro, Linda Yau, Pau...> ;AIDS. 2009 Jul 1
• 276 citations
  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
  Dunne, M. W., Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, Irina Konourina, Andy I. M. Hoepelman, Harry Lampiris, Bernard Hirschel, Pablo Tebas, François Raffi, Be...> ;The New England Journal of Medicine. 2008 Oct 2
• 56 citations
  First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
  Benjamin Young, Kathleen Squires, Parul Patel, Edwin DeJesus, Nicholaos C. Bellos, Daniel S Berger, Denise H. Sutherland-Phillips, Qiming Liao, Mark S. Shaefer, Paul W...> ;AIDS. 2008 Aug 20
• 95 citations
  A 96-Week Comparison of Lopinavir- Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
  D. William Cameron, Barbara A. da Silva, Jose R. Arribas, Robert A. Myers, Nicholaos C. Bellos, Norbert Gilmore, Martin S. King, Barry Bernstein, Scott C. Brun, George...> ;The Journal of Infectious Diseases. 2008 Jul 15
• 72 citations
  T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen
  Jacob Lalezari, Nicholaos C. Bellos, Kunthavi Sathasivam, Gary Richmond, Calvin J. Cohen, Robert A. Myers, David H. Henry, Claire Raskino, Tom Melby, Hugh Murchison, Y...> ;The Journal of Infectious Diseases. 2005 Apr 1
• 160 citations
  SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
  Joseph C. Gathe, Prudence Ive, Robin Wood, Dirk Schürmann, Nicholaos C. Bellos, Edwin DeJesus, Andrzej Gladysz, Cindy Garris, Jane Yeo> ;AIDS. 2004 Jul 23
• 1 citations
  Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial
  Margaret A. Fischl, Alfred F. Burnside, Charles Farthing, Melanie A. Thompson, Nicholaos C. Bellos, Vanessa C. Williams, Teresa L. Kauf, Paul Wannamaker, Mark S. Shaefer> ;Pharmacotherapy. 2003 Nov 1
• 156 citations
  Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
  Kathleen Squires, Anton Pozniak, Gerald Pierone, Corklin R. Steinhart, Daniel S Berger, Nicholaos C. Bellos, Stephen L. Becker, Michael Wulfsohn, Michael D. Miller, Jo...> ;Annals of Internal Medicine. 2003 Sep 2
• 9 citations
  Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
  Michael Sension, Nicholaos C. Bellos, Judy Johnson, Gladys E. Sepulveda, Edwin DeJesus, Jorge Santana, Michael H. Ames, S. Diane Goodwin> ;HIV Clinical Trials. 2002 Sep 1
• 14 citations
  Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
  Harold A. Kessler, Judy Johnson, Stephen E. Follansbee, Michael Sension, Donna Mildvan, Gladys E. Sepulveda, Nicholaos C. Bellos, Seth Hetherington> ;Clinical Infectious Diseases. 2002 Feb 15
• Join now to see all